152 related articles for article (PubMed ID: 34333080)
1. Hydroxychloroquine dose tapering or discontinuation in cutaneous lupus erythematosus after remission: A retrospective multicenter cohort study of 56 patients.
Sonigo G; Jachiet M; Bessis D; Cordel N; Faucon C; Petit A; Cordoliani F; Bagot M; Senet P; Barbaud A; Bouaziz JD; Francès C; Chasset F;
J Am Acad Dermatol; 2022 Jul; 87(1):203-206. PubMed ID: 34333080
[No Abstract] [Full Text] [Related]
2. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
Ugarte A; Porta S; Ríos R; Martinez-Zapico A; Ortego-Centeno N; Agesta N; Ruiz-Irastorza G
Lupus; 2018 Sep; 27(10):1718-1722. PubMed ID: 29635998
[TBL] [Abstract][Full Text] [Related]
3. Use of hydroxychloroquine and risk of major adverse cardiovascular events in patients with lupus erythematosus: A Danish nationwide cohort study.
Haugaard JH; Dreyer L; Ottosen MB; Gislason G; Kofoed K; Egeberg A
J Am Acad Dermatol; 2021 Apr; 84(4):930-937. PubMed ID: 33321159
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic efficacy and adverse events of hydroxychloroquine administration in Japanese systemic/cutaneous lupus erythematosus patients.
Kishi C; Motegi SI; Yasuda M; Ishikawa O
J Dermatol; 2018 Aug; 45(8):1020-1022. PubMed ID: 30133802
[No Abstract] [Full Text] [Related]
5. Adverse cutaneous reactions secondary to hydroxychloroquine in patients with dermatomyositis, lupus erythematosus, and lichen planopilaris.
Akabane AL; Smith GP
J Am Acad Dermatol; 2021 Oct; 85(4):1046-1047. PubMed ID: 33607179
[No Abstract] [Full Text] [Related]
6. Beneficial effect of hydroxychloroquine on cutaneous vasculitis in a Japanese patient with systemic lupus erythematosus.
Kibune N; Shimomura Y; Hasegawa A; Saeki T; Umemori Y; Abe R
J Dermatol; 2017 Apr; 44(4):e52-e53. PubMed ID: 27569899
[No Abstract] [Full Text] [Related]
7. Ototoxicity due to hydroxychloroquine: report of two cases.
Johansen PB; Gran JT
Clin Exp Rheumatol; 1998; 16(4):472-4. PubMed ID: 9706431
[TBL] [Abstract][Full Text] [Related]
8. Use of hydroxychloroquine in dermatology: A multicenter retrospective study in Korea.
Lim JW; Lee JH; Kim HJ
J Dermatol; 2022 Jan; 49(1):173-178. PubMed ID: 34713476
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and factors associated with long-term remission in cutaneous lupus: A longitudinal cohort study of 141 cases.
Fayard D; Francès C; Amoura Z; Breillat P; Mathian A; Senet P; Barbaud A; Arnaud L; Chasset F
J Am Acad Dermatol; 2022 Aug; 87(2):323-332. PubMed ID: 35390427
[TBL] [Abstract][Full Text] [Related]
10. Varied responses to and efficacies of hydroxychloroquine treatment according to cutaneous lupus erythematosus subtypes in Japanese patients.
Ototake Y; Yamaguchi Y; Kanaoka M; Akita A; Ikeda N; Aihara M
J Dermatol; 2019 Apr; 46(4):285-289. PubMed ID: 30719729
[TBL] [Abstract][Full Text] [Related]
11. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study.
Francès C; Cosnes A; Duhaut P; Zahr N; Soutou B; Ingen-Housz-Oro S; Bessis D; Chevrant-Breton J; Cordel N; Lipsker D; Costedoat-Chalumeau N
Arch Dermatol; 2012 Apr; 148(4):479-84. PubMed ID: 22508872
[TBL] [Abstract][Full Text] [Related]
12. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus.
Pelle MT; Callen JP
Arch Dermatol; 2002 Sep; 138(9):1231-3; discussion 1233. PubMed ID: 12224986
[TBL] [Abstract][Full Text] [Related]
13. Continuation Rate, Safety and Efficacy of Hydroxychloroquine Treatment in a Retrospective Cohort of Systemic Lupus Erythematosus in a Japanese Municipal Hospital.
Hosokawa Y; Oiwa H
Intern Med; 2020 Oct; 59(20):2485-2490. PubMed ID: 32641656
[TBL] [Abstract][Full Text] [Related]
14. Unilateral lupus mastitis.
Jiménez-Antón A; Jiménez-Gallo D; Millán-Cayetano JF; Navarro-Navarro I; Linares-Barrios M
Lupus; 2023 Mar; 32(3):438-440. PubMed ID: 36623176
[TBL] [Abstract][Full Text] [Related]
15. Hydroxychloroquine modulates elevated expression of S100 proteins in systemic lupus erythematosus.
Wakiya R; Kameda T; Ueeda K; Nakashima S; Shimada H; Mansour MF; Kato M; Miyagi T; Miyatake N; Kadowaki N; Dobashi H
Lupus; 2019 Jun; 28(7):826-833. PubMed ID: 31068068
[TBL] [Abstract][Full Text] [Related]
16. Correlation of whole blood hydroxychloroquine concentration with cutaneous lupus erythematosus and factors associated with it: First multicenter, cross-sectional analysis in Malaysia.
Peh D; Wan Ahmad Kammal WSL; Beh PJ; Yong ACH; Tan WC; Lim AL; Thevarajah S; Stanslas J; How KN
J Dermatol; 2022 May; 49(5):545-549. PubMed ID: 35067938
[TBL] [Abstract][Full Text] [Related]
17. Safe Introduction of Hydroxychloroquine Focusing on Early Intolerance Due to Adverse Drug Reactions in Patients with Systemic Lupus Erythematosus.
Yoshida Y; Oka N; Yorishima A; Masuda S; Ishitoku M; Araki K; Kohno H; Watanabe H; Sugimoto T; Mokuda S; Hirata S
Intern Med; 2023 Jul; 62(14):2051-2057. PubMed ID: 36384904
[TBL] [Abstract][Full Text] [Related]
18. Impact of smoking in cutaneous lupus erythematosus.
Piette EW; Foering KP; Chang AY; Okawa J; Ten Have TR; Feng R; Werth VP
Arch Dermatol; 2012 Mar; 148(3):317-22. PubMed ID: 22105815
[TBL] [Abstract][Full Text] [Related]
19. [Quinacrine in the treatment of cutaneous lupus erythematosus: practical aspects and a case series].
González-Sixto B; García-Doval I; Oliveira R; Posada C; García-Cruz MA; Cruces M
Actas Dermosifiliogr; 2010; 101(1):54-8. PubMed ID: 20109393
[TBL] [Abstract][Full Text] [Related]
20. Interventions for cutaneous disease in systemic lupus erythematosus.
Hannon CW; McCourt C; Lima HC; Chen S; Bennett C
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD007478. PubMed ID: 33687069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
